Reuters logo
Gilead net profit falls 25 percent on lower hepatitis C sales
May 2, 2017 / 8:26 PM / 7 months ago

Gilead net profit falls 25 percent on lower hepatitis C sales

May 2 (Reuters) - Gilead Sciences Inc on Tuesday reported a 25 percent drop in first-quarter profit as fewer patients were treated with its flagship drugs for hepatitis C, sending shares of the biotechnology company down 2 percent.

Quarterly sales of hepatitis C drugs Sovaldi, Harvoni and Epclusa totaled $2.6 billion, down from $4.3 billion a year earlier. Wall street analysts, on average, expected first-quarter hepatitis C drug sales of $2.65 billion, according to Thomson Reuters I/B/E/S.

Gilead warned earlier this year that sales of the high-priced drugs were declining due to a combination of fewer patients being deemed eligible for treatment and growing competition from other drugmakers.

Gilead’s first-quarter net income fell to $2.7 billion from $3.6 billion a year earlier. Adjusting for one-time items, Gilead said it earned $2.23 a share in the quarter.

Overall revenue fell to $6.5 billion from $7.8 billion.

The company repeated its previous forecast for overall 2017 product sales of $22.5 billion to $24.5 billion.

Shares of Gilead were down nearly 2 percent at $67.30 in after-hours trading. (Reporting by Deena Beasley in Los Angeles; Editing by Matthew Lewis)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below